{"id":411,"date":"2024-09-23T16:27:00","date_gmt":"2024-09-23T07:27:00","guid":{"rendered":"https:\/\/hara-heart.com\/blog\/?p=411"},"modified":"2024-08-14T21:47:18","modified_gmt":"2024-08-14T12:47:18","slug":"sglt2%e9%98%bb%e5%ae%b3%e8%96%ac%ef%bc%9a%e6%80%a5%e6%80%a7%e6%9c%9f%e3%81%ae%e5%bf%83%e4%b8%8d%e5%85%a8%e6%b2%bb%e7%99%82","status":"publish","type":"post","link":"https:\/\/hara-heart.com\/blog\/archives\/411\/","title":{"rendered":"SGLT2\u963b\u5bb3\u85ac\uff1a\u6025\u6027\u671f\u306e\u5fc3\u4e0d\u5168\u6cbb\u7642"},"content":{"rendered":"
\n
\"\"<\/figure>\n<\/div>\n\n\n
SGLT2\u963b\u5bb3\u85ac\u306f\u5f53\u521d2\u578b\u7cd6\u5c3f\u75c5\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u958b\u767a\u3055\u308c\u307e\u3057\u305f\u304c\u3001\u8fd1\u5e74\u306e\u5927\u898f\u6a21\u81e8\u5e8a\u8a66\u9a13\u306b\u3088\u308a\u3001\u5fc3\u4e0d\u5168\u6cbb\u7642\u306b\u304a\u3051\u308b\u6709\u52b9\u6027\u304c\u660e\u3089\u304b\u306b\u306a\u308a\u307e\u3057\u305f\u3002
\u6162\u6027\u5fc3\u4e0d\u5168\u306b\u5bfe\u3059\u308b\u52b9\u679c\u306f\u3001

EMPEROR-Reduced\u8a66\u9a13(1)
EMPEROR-Preserved\u8a66\u9a13(2)
DAPA-HF\u8a66\u9a13(3)
DELIVER\u8a66\u9a13(4)

\u306b\u3088\u3063\u3066\u5b9f\u8a3c\u3055\u308c\u3001\u73fe\u5728\u3067\u306f\u6162\u6027\u5fc3\u4e0d\u5168\u6cbb\u7642\u306e\u300c\u30d5\u30a1\u30f3\u30bf\u30b9\u30c6\u30a3\u30c3\u30af\uff14\u300d\u306e\u4e00\u3064<\/mark>\u3068\u3057\u3066\u63a8\u5968\u3055\u308c\u3066\u3044\u307e\u3059\u3002


\u3055\u3089\u306b\u3001\u6025\u6027\u671f\uff08\u6025\u306b\u767a\u75c7\u30fb\u60aa\u5316\u3057\u305f\uff09\u5fc3\u4e0d\u5168\u306b\u304a\u3044\u3066\u3082\u3001

SOLOIST-WHF\u8a66\u9a13(5)
\u2022  \u5bfe\u8c61\uff1a\u6025\u6027\u5fc3\u4e0d\u5168\u3067\u5165\u9662\u3057\u305f2\u578b\u7cd6\u5c3f\u75c5\u60a3\u80051,222\u4eba 
\u2022  \u65b9\u6cd5\uff1a\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u76f2\u691c\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u8a66\u9a13 
\u2022  \u7d50\u679c\uff1a\u30bd\u30bf\u30b0\u30ea\u30d5\u30ed\u30b8\u30f3\u306e\u6295\u4e0e\u306b\u3088\u308a\u3001\u5fc3\u8840\u7ba1\u6b7b\u4ea1\u3084\u5fc3\u4e0d\u5168\u306b\u3088\u308b\u5165\u9662\u30fb\u7dca\u6025\u53d7\u8a3a\u306e\u30ea\u30b9\u30af\u304c33%\u4f4e\u4e0b

EMPULSE\u8a66\u9a13(6)
\u2022  \u5bfe\u8c61\uff1a\u6025\u6027\u5fc3\u4e0d\u5168\u3067\u5165\u9662\u3057\u305f\u60a3\u8005530\u4eba\uff08\u7cd6\u5c3f\u75c5\u306e\u6709\u7121\u306f\u554f\u308f\u305a\uff09 
\u2022  \u65b9\u6cd5\uff1a\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u76f2\u691c\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u8a66\u9a13 
\u2022  \u7d50\u679c\uff1a\u30a8\u30f3\u30d1\u30b0\u30ea\u30d5\u30ed\u30b8\u30f3\u306e\u6295\u4e0e\u306b\u3088\u308a\u300190\u65e5\u4ee5\u5185\u306e\u5fc3\u8840\u7ba1\u6b7b\u4ea1\u3084\u5fc3\u4e0d\u5168\u306b\u3088\u308b\u518d\u5165\u9662\u30ea\u30b9\u30af\u304c36%\u4f4e\u4e0b

\u306b\u3088\u3063\u3066\u3001\u6025\u6027\u671f\u5fc3\u4e0d\u5168\u3078\u306e\u52b9\u679c\u3082\u793a\u3055\u308c\u3066\u304a\u308a\u307e\u3059\u3002

\u6025\u6027\u671f\u5fc3\u4e0d\u5168\u306e\u6cbb\u7642\u306f\u3055\u3058\u52a0\u6e1b\u304c\u96e3\u3057\u3044\u306e\u3067\u3059\u304c\u3001\u5f53\u9662\u3067\u306f\u3001\u5f93\u6765\u304b\u3089\u7528\u3044\u3089\u308c\u3066\u3044\u305f\u30eb\u30fc\u30d7\u5229\u5c3f\u85ac\u3001\u8840\u7ba1\u62e1\u5f35\u85ac\u306a\u3069\u3068\u3068\u3082\u306b\u3001\u5fc3\u4e0d\u5168\u306e\u91cd\u75c7\u5ea6\u3001\u8840\u5727\u3001\u814e\u6a5f\u80fd\u306a\u3069\u3092\u8e0f\u307e\u3048\u3066\u3001SGLT2\u963b\u5bb3\u85ac\u3082\u7528\u3044\u3066\u5bfe\u5fdc<\/mark>\u3092\u3057\u3066\u304a\u308a\u307e\u3059\u3002



1.\tPacker M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020;383:1413-1424.
2.\tAnker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021;385:1451-1461.
3.\tMcMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019;381:1995-2008.
4.\tSolomon SD, McMurray JJV, Claggett B et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022;387:1089-1098.
5.\tBhatt DL, Szarek M, Steg PG et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med 2021;384:117-128.
6.\tVoors AA, Angermann CE, Teerlink JR et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022;28:568-574.

<\/pre>\n","protected":false},"excerpt":{"rendered":"
SGLT2\u963b\u5bb3\u85ac\u306f\u5f53\u521d2\u578b\u7cd6\u5c3f\u75c5\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u958b\u767a\u3055\u308c\u307e\u3057\u305f\u304c\u3001\u8fd1\u5e74\u306e\u5927\u898f\u6a21\u81e8\u5e8a\u8a66\u9a13\u306b\u3088\u308a\u3001\u5fc3\u4e0d\u5168\u6cbb\u7642\u306b\u304a\u3051\u308b\u6709\u52b9\u6027\u304c\u660e\u3089\u304b\u306b\u306a\u308a\u307e\u3057\u305f\u3002\u6162\u6027\u5fc3\u4e0d\u5168\u306b\u5bfe\u3059\u308b\u52b9\u679c\u306f\u3001EMPEROR-Reduced\u8a66\u9a13(1)EMPEROR- […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-411","post","type-post","status-publish","format-standard","category-3"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\n\t\t